Nordic Pharma, a subsidiary of Nordic Group BV, is advancing the U.S. introduction of LACRIFILL® Canalicular Gel, a novel therapy for dry eye, during the 2024 American Academy of Ophthalmology (AAO) meeting. Following its U.S. launch in April, LACRIFILL will be showcased to leading ophthalmologists as an innovative option for managing dry eye symptoms. The gel is made from cross-linked hyaluronic acid and has received FDA clearance for temporarily blocking tear drainage by occluding the canalicular system. This approach allows the eyes to retain natural tears for an extended period, providing a new level of comfort and symptom relief for patients. The gel is customized for each patient and delivered through a straightforward in-office procedure, with results lasting up to six months. The treatment is also reimbursable under an existing CPT code.
The October issue of the Journal of Cataract and Refractive Surgery (JCRS) features a pivotal study on LACRIFILL, authored by renowned experts including Dr. Mark Packer, Dr. Richard Lindstrom, and Dr. Vance Thompson, among others. The study demonstrated the safety and effectiveness of the gel as a lacrimal occlusion device for dry eye therapy. Clinical results indicated significant improvement in dry eye symptoms, with notable gains in Schirmer score, Ocular Surface Disease Index (OSDI), corneal staining, and Tear Breakup Time (TBUT), sustained for six months. Dye disappearance testing confirmed that the cross-linked hyaluronic acid gel remained in place throughout this period. The device proved to be safe, well-tolerated, easy to insert, and easy to remove after the six-month duration.
Dr. Neel R. Desai, from the Eye Institute of West Florida, has integrated LACRIFILL into his first-line treatment protocols for dry eye management. He praised the therapy for its simplicity, comfort, and immediate relief, even noting positive personal experience with the treatment. According to Dr. Desai, LACRIFILL has shown promise not only in treating dry eye but also in optimizing the ocular surface before refractive cataract surgery.
During the AAO meeting, attendees are invited to visit booth 4062 on October 19 for a detailed session on dry eye disease management, featuring LACRIFILL® Canalicular Gel and reimbursement options. The discussion will be followed by a Q&A session led by Kevin J. Corcoran, a principal at Corcoran & Corcoran, providing an opportunity for attendees to deepen their understanding and address any queries. Orders for LACRIFILL can also be placed at the booth.
Nordic Pharma will be a prominent presence at the AAO as the Premier Sponsor of the Women in Ophthalmology (WIO) Awards Ceremony and Networking Reception. This sponsorship underscores the company’s commitment to advancing ophthalmic care and supporting the achievements of exceptional women in the field. Dr. Lisa M. Nijm, an ophthalmologist and attorney at Warrenville Eyecare & LASIK, highlighted the significance of Nordic Pharma’s involvement, stating that it reflects a dedication to making a lasting impact on both patient care and the professional community.
For more information on LACRIFILL Canalicular Gel, its benefits, and ordering details, visit lacrifill.com. Nordic Pharma aims to provide healthcare professionals with a transformative solution for dry eye, offering a personalized and effective approach that addresses the complexities of this condition.
About Nordic Group BV
Nordic Group BV is a privately held, mid-sized international pharmaceutical company focused on the development and marketing of specialty products. The portfolio enhancement has been achieved through targeted developments and acquisitions to lay the foundations in eye care, rheumatology and women’s health. Nordic Group has established deep roots throughout Europe, and more recently, has expanded outside of Europe with new acquisitions worldwide.
Nordic Group is part of SEVER Life Sciences, a holding company established in 2019 that brings together three diverse but complementary companies offering a broad range of products, pharmaceutical development services and delivery technologies.
About Nordic Pharma, Inc.
Nordic Pharma, Inc., a subsidiary of Nordic Group BV, associated with well-established global biopharmaceutical companies, is uniquely positioned to leverage its expertise in bringing biotechnology-derived drugs to market, sterile manufacturing and other advanced technologies.
